Sapience Therapeutics

Executive Summary

Sapience Therapeutics is a clinical-stage biotechnology company pioneering peptide therapeutics to target traditionally 'undruggable' oncogenic proteins. Based in Tarrytown, New York, and founded in 2009, the company has advanced two first-in-class candidates into Phase 2 clinical trials. Its mission is to redefine druggability in oncology, aiming to deliver new treatments for patients with limited options. The company's proprietary platform enables the discovery of peptides that disrupt intracellular protein-protein interactions, a class of targets historically considered intractable. With a focus on high-unmet-need cancers, Sapience's lead programs target key oncogenic drivers, potentially offering novel mechanisms of action beyond conventional small molecules and biologics. The company remains private and has not disclosed total funding, but its progression to Phase 2 suggests meaningful investor support and clinical validation. The near-term focus is on generating proof-of-concept data from ongoing trials, which could de-risk the platform and attract partnership or financing opportunities.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead peptide candidate in solid tumors40% success
• Q4 2026Initiation of a second Phase 2 trial in a new indication60% success
• TBDPotential partnership or licensing deal for the peptide platform30% success